Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Jun;5(6):810-7.
doi: 10.1097/jto.0b013e3181d89f95.

Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633

Stephen L Graziano  1 , Lin Gu, Xiaofei Wang, Arthur H Tatum, Robin T Vollmer, Gary M Strauss, Robert Kratzke, Arkadiusz Z Dudek, Everett E Vokes, Mark R Green; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group
Affiliations
Clinical Trial

Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633

Stephen L Graziano et al. J Thorac Oncol. 2010 Jun.

Abstract

Introduction: Cancer and Leukemia Group B 9633 was a phase III trial that randomized patients with stage IB non-small cell lung cancer to observation or four cycles of carboplatin and paclitaxel. A statistically significant effect in favor of adjuvant chemotherapy was seen for disease-free survival (DFS) and overall survival (OS) in the subgroup of patients with tumors > or =4 cm. A laboratory companion study was conducted to see whether molecular and clinical factors could provide additional prognostic information.

Methods: Formalin-fixed, paraffin-embedded blocks were obtained for 250 of the 344 patients enrolled. Immunohistochemical staining for bcl-2, p53, blood group antigen A, and mucin was correlated with DFS and OS.

Results: The prevalence of the markers was bcl-2, 17%; p53, 47%; blood group antigen A, 25%; and mucin, 45%. Univariate analysis for DFS showed a statistically significant effect for the presence of mucin (p = 0.0005) and p53 (p = 0.05) and for OS showed a significant effect for mucin (p = 0.0005). In the multivariate Cox model, there was a statistically significant association between shorter DFS and presence of mucin (p = 0.002; hazard ratio [HR] 2.05) and p53 (p = 0.003; HR 1.95) and between shorter OS and presence of mucin (p = 0.004; HR 2.03) and p53 (p = 0.0005; HR 2.30). Of the clinical factors, male gender and larger tumor volume were also significant adverse prognostic factors (p 0.05).

Conclusions: A statistically significant association between shorter DFS and OS was seen for the patients with p53 protein expression, mucin expression, male gender, and larger tumors in this cohort of patients with stage IB non-small cell lung cancer treated on Cancer and Leukemia Group B 9633.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1A. Kaplan-Meier DFS curve for mucin. Figure 1B. Kaplan-Meier OS curve for mucin.
Figure 1
Figure 1
Figure 1A. Kaplan-Meier DFS curve for mucin. Figure 1B. Kaplan-Meier OS curve for mucin.
Figure 2
Figure 2
Figure 2A. Kaplan-Meier DFS curve for p53. Figure 2B. Kaplan-Meier OS curve for p53.
Figure 2
Figure 2
Figure 2A. Kaplan-Meier DFS curve for p53. Figure 2B. Kaplan-Meier OS curve for p53.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. WHO. Global cancer rates could increase 50% to 15 million by 2020 [WHO Web site] Apr 3, 2003. [Accessed Jan 18, 2010]. Available at: http://www.who.int/mediacentre/news/releases/2003/pr27/en.
    1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360. - PubMed
    1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;52:2589–2597. - PubMed
    1. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727. - PubMed

Publication types

Grants and funding